Study · Randomized controlled trial · n = 173 · 2019

9 results

Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial.

Beguería R, García D, Vassena R, Rodríguez A

Human reproduction (Oxford, England)1 May 2019Cited by 80 (Europe PMC)

PMID30927417DOI10.1093/humrep/dez034PepBankPUB-30927417

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In oocyte donors, mature oocyte numbers did not differ between ganirelix and MPA.
In plain wordsIn oocyte donors, mature oocyte numbers did not differ between ganirelix and MPA.
Peptide
Ganirelix
Outcome
No significant changeMature oocytes retrieved
Study
n = 173
Comparator
Medroxyprogesterone acetate
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Measurements
Mature oocytes
14.6 oocytes
ganirelix mean
Mature oocytes SD
7 oocytes
ganirelix
Mature oocytes
15.1 oocytes
MPA mean
Mature oocytes SD
8.3 oocytes
MPA
95% CI of the difference in MII retrieved
−2.78 to −1.83 oocytes
between groups
Source sentences
Summary
The number of MII retrieved was no different: 15.1 (SD 8.3) with MPA and 14.6 (SD 7.0), 95% CI of the difference -2.78, -1.83 excluding the pre-defined non-inferiority limit (-3).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized clinical trial, open-label, single center, to assess the non-inferiority of MPA (10 mg/day) versus ganirelix (0.25 mg/day) from Day 7, in ovarian stimulation cycles triggered with triptoreline acetate.
Summary · context
Overall, 252 oocyte donors were selected (eligible), 216 were randomized and 173 reached OPU: 86 under MPA and 87 under ganirelix.
Report a problemFND-3092741703
02HumanRandomized controlled trialEfficacy outcome
Recipients received similar numbers of mature oocytes from ganirelix and MPA donor cycles.
In plain wordsRecipients received similar numbers of mature oocytes from ganirelix and MPA donor cycles.
Peptide
Ganirelix
Outcome
No significant changeMature oocytes assigned per recipient
Study
n: not reported in source
Comparator
Medroxyprogesterone acetate
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Measurements
Mature oocytes assigned
6.6 oocytes
ganirelix mean
Mature oocytes assigned SD
1.2 oocytes
ganirelix
Mature oocytes assigned
6.7 oocytes
MPA mean
Mature oocytes assigned SD
1.2 oocytes
MPA
Source sentences
Summary
The mean number of MII assigned to each recipients was 6.7 (SD 1.2) in MPA and 6.6 (SD 1.2) in ganirelix (P = 0.58).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized clinical trial, open-label, single center, to assess the non-inferiority of MPA (10 mg/day) versus ganirelix (0.25 mg/day) from Day 7, in ovarian stimulation cycles triggered with triptoreline acetate.
Summary · context
Overall, 252 oocyte donors were selected (eligible), 216 were randomized and 173 reached OPU: 86 under MPA and 87 under ganirelix.
Report a problemFND-3092741704
03HumanRandomized controlled trialEfficacy outcome
Fertilization rates were similar for oocytes from ganirelix and MPA donor cycles.
In plain wordsFertilization rates were similar for oocytes from ganirelix and MPA donor cycles.
Peptide
Ganirelix
Outcome
No significant changeFertilization rate
Study
n: not reported in source
Comparator
Medroxyprogesterone acetate
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Measurements
Fertilization rate
74%
ganirelix
Fertilization rate
76%
MPA
Source sentences
Summary
MII were fertilized with partner sperm in 84% cycles overall and fertilization rate was 76% in MPA versus 74% in ganirelix (P = 0.34).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized clinical trial, open-label, single center, to assess the non-inferiority of MPA (10 mg/day) versus ganirelix (0.25 mg/day) from Day 7, in ovarian stimulation cycles triggered with triptoreline acetate.
Summary · context
Overall, 252 oocyte donors were selected (eligible), 216 were randomized and 173 reached OPU: 86 under MPA and 87 under ganirelix.
Report a problemFND-3092741705
04HumanRandomized controlled trialEfficacy outcome
In oocyte donors, stimulation duration was similar with ganirelix and MPA, at 11.2 days.
In plain wordsIn oocyte donors, stimulation duration was similar with ganirelix and MPA.
Peptide
Ganirelix
Outcome
Direction not reportedStimulation duration
Study
n = 173
Comparator
Medroxyprogesterone acetate
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Measurements
Stimulation duration
11.2 days
both groups
Source sentences
Summary
Duration of stimulation was similar in both groups (11.2 days), as well as the total gonadotropin dose up to trigger (2162 IU in MPA and 2163 IU in ganirelix).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized clinical trial, open-label, single center, to assess the non-inferiority of MPA (10 mg/day) versus ganirelix (0.25 mg/day) from Day 7, in ovarian stimulation cycles triggered with triptoreline acetate.
Summary · context
Overall, 252 oocyte donors were selected (eligible), 216 were randomized and 173 reached OPU: 86 under MPA and 87 under ganirelix.
Report a problemFND-3092741701
05HumanRandomized controlled trialEfficacy outcome
In oocyte donors, total gonadotropin dose was similar with ganirelix and MPA.
In plain wordsIn oocyte donors, gonadotropin dose was similar with ganirelix and MPA.
Peptide
Ganirelix
Outcome
Direction not reportedTotal gonadotropin dose
Study
n = 173
Comparator
Medroxyprogesterone acetate
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Measurements
Gonadotropin dose
2163 IU
ganirelix
Gonadotropin dose
2162 IU
MPA
Source sentences
Summary
Duration of stimulation was similar in both groups (11.2 days), as well as the total gonadotropin dose up to trigger (2162 IU in MPA and 2163 IU in ganirelix).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized clinical trial, open-label, single center, to assess the non-inferiority of MPA (10 mg/day) versus ganirelix (0.25 mg/day) from Day 7, in ovarian stimulation cycles triggered with triptoreline acetate.
Summary · context
Overall, 252 oocyte donors were selected (eligible), 216 were randomized and 173 reached OPU: 86 under MPA and 87 under ganirelix.
Report a problemFND-3092741702
06HumanObservational studyEfficacy outcome
In nonrandomized recipients, ganirelix donor cycles were linked to higher biochemical pregnancy rates than MPA donor cycles.
In plain wordsIn recipients, ganirelix donor cycles were linked to higher biochemical pregnancy rates than MPA cycles.
Peptide
Ganirelix
Outcome
IncreaseBiochemical pregnancy rate
Study
n: not reported in source
Comparator
Medroxyprogesterone acetate
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Measurements
Biochemical pregnancy rate
57%
ganirelix
Biochemical pregnancy rate
44%
MPA
Source sentences
Summary
Biochemical pregnancy rate was 44 versus 57% (P = 0.023)
4 context sentences(design, population, supporting numbers)
Summary · context
In spite of similar recipients and cycle characteristics, reproductive outcomes were unexpectedly lower with MPA.
Summary · context
Although oocyte recipient and ET characteristics are similar among groups, this RCT has been designed under a hypothesis of non-inferiority in the number of MII obtained and recipients were not randomized; therefore, the reproductive outcomes in recipients should be evaluated with extreme caution.
Summary · context
Randomized clinical trial, open-label, single center, to assess the non-inferiority of MPA (10 mg/day) versus ganirelix (0.25 mg/day) from Day 7, in ovarian stimulation cycles triggered with triptoreline acetate.
Summary · context
Overall, 252 oocyte donors were selected (eligible), 216 were randomized and 173 reached OPU: 86 under MPA and 87 under ganirelix.
Report a problemFND-3092741706
07HumanObservational studyEfficacy outcome
In nonrandomized recipients, ganirelix donor cycles were linked to higher clinical pregnancy rates than MPA donor cycles.
In plain wordsIn recipients, ganirelix donor cycles were linked to higher clinical pregnancy rates than MPA cycles.
Peptide
Ganirelix
Outcome
IncreaseClinical pregnancy rate
Study
n: not reported in source
Comparator
Medroxyprogesterone acetate
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Measurements
Clinical pregnancy rate
46%
ganirelix
Clinical pregnancy rate
31%
MPA
Source sentences
Summary
clinical pregnancy rate 31 versus 46% (P = 0.006)
4 context sentences(design, population, supporting numbers)
Summary · context
In spite of similar recipients and cycle characteristics, reproductive outcomes were unexpectedly lower with MPA.
Summary · context
Although oocyte recipient and ET characteristics are similar among groups, this RCT has been designed under a hypothesis of non-inferiority in the number of MII obtained and recipients were not randomized; therefore, the reproductive outcomes in recipients should be evaluated with extreme caution.
Summary · context
Randomized clinical trial, open-label, single center, to assess the non-inferiority of MPA (10 mg/day) versus ganirelix (0.25 mg/day) from Day 7, in ovarian stimulation cycles triggered with triptoreline acetate.
Summary · context
Overall, 252 oocyte donors were selected (eligible), 216 were randomized and 173 reached OPU: 86 under MPA and 87 under ganirelix.
Report a problemFND-3092741707
08HumanObservational studyEfficacy outcome
In nonrandomized recipients, ganirelix donor cycles were linked to higher ongoing pregnancy rates than MPA donor cycles.
In plain wordsIn recipients, ganirelix donor cycles were linked to higher ongoing pregnancy rates than MPA cycles.
Peptide
Ganirelix
Outcome
IncreaseOngoing pregnancy rate
Study
n: not reported in source
Comparator
Medroxyprogesterone acetate
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Measurements
Ongoing pregnancy rate
40%
ganirelix
Ongoing pregnancy rate
27%
MPA
Source sentences
Summary
ongoing pregnancy rate 27 versus 40%, (P = 0.015)
4 context sentences(design, population, supporting numbers)
Summary · context
In spite of similar recipients and cycle characteristics, reproductive outcomes were unexpectedly lower with MPA.
Summary · context
Although oocyte recipient and ET characteristics are similar among groups, this RCT has been designed under a hypothesis of non-inferiority in the number of MII obtained and recipients were not randomized; therefore, the reproductive outcomes in recipients should be evaluated with extreme caution.
Summary · context
Randomized clinical trial, open-label, single center, to assess the non-inferiority of MPA (10 mg/day) versus ganirelix (0.25 mg/day) from Day 7, in ovarian stimulation cycles triggered with triptoreline acetate.
Summary · context
Overall, 252 oocyte donors were selected (eligible), 216 were randomized and 173 reached OPU: 86 under MPA and 87 under ganirelix.
Report a problemFND-3092741708
09HumanObservational studyEfficacy outcome
In nonrandomized recipients, live birth rates did not differ significantly between ganirelix and MPA donor cycles.
In plain wordsIn recipients, live birth rates did not differ significantly between ganirelix and MPA donor cycles.
Peptide
Ganirelix
Outcome
No significant changeLive birth rate
Study
n: not reported in source
Comparator
Medroxyprogesterone acetate
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Measurements
Live birth rate
31%
ganirelix
Live birth rate
22%
MPA
Source sentences
Summary
live birth rate 22 versus 31%, (P = 0.10).
4 context sentences(design, population, supporting numbers)
Summary · context
In spite of similar recipients and cycle characteristics, reproductive outcomes were unexpectedly lower with MPA.
Summary · context
Although oocyte recipient and ET characteristics are similar among groups, this RCT has been designed under a hypothesis of non-inferiority in the number of MII obtained and recipients were not randomized; therefore, the reproductive outcomes in recipients should be evaluated with extreme caution.
Summary · context
Randomized clinical trial, open-label, single center, to assess the non-inferiority of MPA (10 mg/day) versus ganirelix (0.25 mg/day) from Day 7, in ovarian stimulation cycles triggered with triptoreline acetate.
Summary · context
Overall, 252 oocyte donors were selected (eligible), 216 were randomized and 173 reached OPU: 86 under MPA and 87 under ganirelix.
Report a problemFND-3092741709

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials7

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

7 trials · 1 not yet recruiting · 5 completed · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 3NCT05326087

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A

ShangHai Ji Ai Genetics & IVF Instituten = 204est. 1 Jun 2026 to est. 1 Dec 2028

Preimplantation Genetic Testing · Progestin-primed Ovarian Stimulation · Polycystic Ovarian Syndrome · GnRH Antagonist

Trial page ClinicalTrials.govUpdated 2 Feb 2026

Status unknownPhase 4NCT06637189

Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol with GnRH Antagonists for Ovarian Stimulation in Patients Undergoing DUOSTIM with Embryo Accumulation for PGT-A.

Ginefivn = 144est. 15 Oct 2024 to est. 31 Dec 2025

Stimulation in the Ovary · Embryo · Oocyte · Oocyte Retrieval · Fertilization in Vitro · Blastocyst · PGT-A

Trial page ClinicalTrials.govUpdated 15 Oct 2024

CompletedPhase 4NCT05954962

Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation.

Instituto Bernabeun = 15023 Dec 2023 to 30 Aug 2025

IVF

Trial page ClinicalTrials.govUpdated 27 Mar 2026

CompletedNot applicableNCT05767086

Comparison of 3 Different Protocols for Preventing Premature Ovulation in Ovarian Stimulation Cycles

Bezmialem Vakif Universityn = 29715 Mar 2023 to 30 Sept 2024

Infertility

Trial page ClinicalTrials.govUpdated 15 Oct 2024

CompletedNot applicableNCT04989348

Euploid Rate of Blastocyst Derived From PPOS VS Antagonist Protocol

Shanghai First Maternity and Infant Hospitaln = 2404 Aug 2021 to 20 Feb 2024

IVF

Trial page ClinicalTrials.govUpdated 28 Feb 2024

CompletedPhase 3NCT04414748

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A

ShangHai Ji Ai Genetics & IVF Instituten = 40010 Jun 2020 to 27 May 2025

Preimplantation Genetic Testing · Progestin-primed Ovarian Stimulation · Euploid Rate · GnRH Antagonist

Trial page ClinicalTrials.govUpdated 31 May 2025

CompletedPhase 3NCT04414761

Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response

ShangHai Ji Ai Genetics & IVF Instituten = 7844 Jun 2020 to 10 Oct 2022

IVF · GnRH Antagonist · PPOS

Trial page ClinicalTrials.govUpdated 30 Aug 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.